IRON Disc Medicine, Inc.
Company Analysis
Latest News
Disc Medicine reports $682.8M preliminary third quarter cash and prices $450M upsized public offering
Disc Medicine announced preliminary third quarter 2026 cash results and the pricing of an upsized public offering of common stock. The company intends to use...
Disc Medicine Prices Upsized $450 Million Public Offering
Disc Medicine priced an upsized public offering of 6 million shares of its common stock. The shares are priced at $75.00 each. The company expects gross...
Disc Medicine's Bitopertin Meets All Endpoints in Pivotal Phase 3 EPP Trial
Disc Medicine, Inc. announced positive topline results from its pivotal Phase 3 APOLLO trial of bitopertin for treating erythropoietic protoporphyria (EPP)....
Disc Medicine Reports Positive Phase 2 Trial Results for DISC-3405 in Polycythemia Vera
Disc Medicine, Inc. announced positive initial results from its RESTORE-PV Phase 2 clinical trial of DISC-3405 for patients with polycythemia vera (PV). The...
OrbiMed Advisors reduces Disc Medicine stake by two-thirds
OrbiMed Advisors, a major healthcare-focused investment firm, significantly cut its stake in Disc Medicine by 66.51% during the second quarter of 2026....